Harvard Bioscience (HBIO) Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Leases data on file, last reported at $6.7 million in Q1 2026.

• Quarterly Leases fell 7.59% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 7.59% YoY) and the FY2025 annual result came in at $7.2 million, up 16.96% from the prior year.
• Leases slipped to $6.7 million in Q1 2026 per HBIO's latest filing, from $7.2 million in the prior quarter.
• Across five years, Leases topped out at $7.5 million in Q3 2025 and bottomed at $4.4 million in Q1 2024.
• The 5-year median for Leases is $6.1 million (2024), against an average of $6.0 million.
• The widest annual swing landed in 2024, when Leases retreated 20.82%; it then soared 67.08% in 2025.
• Tracing HBIO's Leases over 5 years: stood at $5.8 million in 2022, then retreated by 17.93% to $4.8 million in 2023, then grew by 28.47% to $6.1 million in 2024, then increased by 16.96% to $7.2 million in 2025, then retreated by 6.16% to $6.7 million in 2026.
• Per Business Quant, the three latest HBIO Leases figures stand at $6.7 million (Q1 2026), $7.2 million (Q4 2025), and $7.5 million (Q3 2025).

Peer Comparison